target icon View trials by
therapeutic target
phase icon View trials
by phase
cancer type icon View trials by
cancer type

Phase 3

Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
MCL
Pirtobrutinib (LOXO-305)
Enrolling
Enrolling
Prostate Cancer
Abemaciclib
Enrolling
Prostate Cancer
Abemaciclib
Enrolling
Medullary Thyroid Cancer
Selpercatinib
Enrolling
Enrolling
Enrolling

Phase 2

Enrolling
CLL/SLL or NHL
Pirtobrutinib (LOXO-305)
Breast Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
Enrolling
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
Selpercatinib
Enrolling
Pediatric Cancer
Selpercatinib
Enrolling

Phase 1

Enrolling
Advanced Hematologic Malignancies
LOXO-338
Breast Cancer
Abemaciclib
Enrolling
Pediatric Cancer
Abemaciclib
Enrolling
Advanced Hematologic Malignancies
LY3410738
Enrolling
Advanced Solid Tumors
LY3410738
Enrolling
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982
Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260
Enrolling
Advanced Solid Tumors
LOXO-783
Enrolling
Breast Cancer or Endometrial Cancer
Imlunestrant
Enrolling

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.